In­ven­ti­va rais­es $44M as it preps for a PhI­II NASH pro­gram, up­com­ing IIb read­out

French biotech In­ven­ti­va has raised about $44 mil­lion dol­lars from a group of ven­ture back­ers lured by the po­ten­tial of an up­com­ing late-stage ef­fort on NASH. And one of those back­ers, Paris-based Sofinno­va Part­ners, is fund­ing the com­pa­ny out of a brand new crossover fund that launched about a week ago with $340 mil­lion.

The biotech’s pipeline is topped by lan­i­fi­bra­nor (IVA337), de­signed to spur three PPAR (per­ox­i­some pro­lif­er­a­tor-ac­ti­vat­ed re­cep­tor) iso­forms — α, δ and γ — in fight­ing NASH. It’s al­so be­ing ad­vanced for sys­temic scle­ro­sis, a rare dis­ease which trig­gers pro­gres­sive or­gan fail­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.